{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:07:19Z","timestamp":1788988039513,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF20OC0064556"],"award-info":[{"award-number":["NNF20OC0064556"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.healun.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:16:34Z","timestamp":1788138994000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial"],"prefix":"10.1016","author":[{"given":"Mads Kristian","family":"Ersb\u00f8ll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5244-0399","authenticated-orcid":false,"given":"Jesper","family":"Kj\u00e6rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7043-4917","authenticated-orcid":false,"given":"Karin","family":"Waidtl\u00f8w","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-1466","authenticated-orcid":false,"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2144-341X","authenticated-orcid":false,"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-1247","authenticated-orcid":false,"given":"Kasper","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.healun.2026.07.008_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.healun.2026.07.008_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.115.016522","article-title":"Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry","volume":"133","author":"Delcroix","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.healun.2026.07.008_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predictors of survival in pulmonary arterial hypertension: the REVEAL Registry","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.healun.2026.07.008_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.healun.2026.07.008_bib5","first-page":"1235","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"8","author":"Hoeper","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.healun.2026.07.008_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.2369","article-title":"The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study","volume":"24","author":"Rosenkranz","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.healun.2026.07.008_bib7","first-page":"1082","article-title":"Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: a COMPERA analysis","volume":"42","author":"Rosenkranz","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2026.07.008_bib8","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1073\/pnas.0605080104","article-title":"Alterations of cellular bioenergetics in pulmonary artery endothelial cells","volume":"104","author":"Xu","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.healun.2026.07.008_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1164\/rccm.201306-1086OC","article-title":"Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension","volume":"189","author":"Hemnes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2026.07.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201206-029OC","article-title":"Fasting 2\u2013deoxy-2\u2013[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year","volume":"10","author":"Lundgrin","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.healun.2026.07.008_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1086\/681227","article-title":"Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy","volume":"5","author":"Talati","year":"2015","journal-title":"Pulm Circ"},{"issue":"15","key":"10.1016\/j.healun.2026.07.008_bib12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.healun.2026.07.008_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2026.07.008_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.healun.2026.07.008_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.healun.2026.07.008_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02400-2024","article-title":"Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis","volume":"66","author":"Meservey","year":"2025","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.healun.2026.07.008_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.013481","article-title":"Use of SGLT2 (sodium-glucose cotransporter 2) inhibitors in pulmonary hypertension","volume":"19","author":"Aguado","year":"2026","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.healun.2026.07.008_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Validation of the REVEAL Lite 2 risk assessment score in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"CHEST"},{"issue":"2","key":"10.1016\/j.healun.2026.07.008_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/14034948211058060","article-title":"Danish population health measured by the EQ-5D-5L","volume":"51","author":"Jensen","year":"2023","journal-title":"Scand J Public Health"},{"issue":"4","key":"10.1016\/j.healun.2026.07.008_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/hc2901.093198","article-title":"Exercise pathophysiology in patients with primary pulmonary hypertension","volume":"104","author":"Sun","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2026.07.008_bib21","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/CIRCULATIONAHA.115.019351","article-title":"Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension","volume":"133","author":"Brittain","year":"2016","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.healun.2026.07.008_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.healun.2026.07.008_bib23","doi-asserted-by":"crossref","first-page":"L435","DOI":"10.1152\/ajplung.00169.2015","article-title":"Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake","volume":"309","author":"Graham","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.healun.2026.07.008_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/2045-8932.97606","article-title":"Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming","volume":"2","author":"Fessel","year":"2012","journal-title":"Pulm Circ"},{"issue":"16","key":"10.1016\/j.healun.2026.07.008_bib25","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.healun.2026.07.008_bib26","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2026.07.008_bib27","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A4975","article-title":"Overall survival of patients on sotatercept: an analysis of STELLAR and SOTERIA trials","volume":"211","author":"Thakur","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.healun.2026.07.008_bib28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2026.07.008_bib29","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.healun.2026.07.008_bib30","first-page":"2331","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McMurray","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2026.07.008_bib31","article-title":"The prognostic impact of serum uric acid on disease severity and 5-year mortality in patients with idiopathic pulmonary artery hypertension","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.healun.2026.07.008_bib32","first-page":"2583","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the EXACT-HF study","volume":"65","author":"Givertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.healun.2026.07.008_bib33","article-title":"A pilot study of allopurinol in pulmonary arterial hypertension","volume":"11","author":"Hopper","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.healun.2026.07.008_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular\u2013pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.healun.2026.07.008_bib35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ehf2.15103","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on the \u201cforgotten\u201d right ventricle","author":"Qu","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2026.07.008_bib36","doi-asserted-by":"crossref","unstructured":"Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. doi:10.1161\/CIRCULATIONAHA.123.065061.","DOI":"10.1161\/CIRCULATIONAHA.123.065061"},{"issue":"6","key":"10.1016\/j.healun.2026.07.008_bib37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes and heart failure: the SUGAR-DM-HF randomized clinical trial","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.healun.2026.07.008_bib38","first-page":"146","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure with reduced and preserved ejection fraction: the EMPERIAL trials","volume":"9","author":"Abraham","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.healun.2026.07.008_bib39","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324982601987X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324982601987X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:15:55Z","timestamp":1788984955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105324982601987X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S105324982601987X"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2026.07.008","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}